Interfering with de novo lipogenesis by pharmacologically mimicking the AMPK inhibitory phosphorylation of ACC1 and ACC2 effectively reduces DEN-induced HCC and the growth of HCC cells, in a cell-autonomous manner, in vitro and in vivo [63]. Here, BCL2A1 is linked to hepatocellular carcinoma.